

# Gene-level analysis of rare variants in 363,977 whole exome sequences identifies an association of *GIGYF1* loss of function with diabetes

Aimee M. Deaton<sup>1</sup>, Margaret M. Parker<sup>1</sup>, Lucas D. Ward<sup>1</sup>, Alexander O. Flynn-Carroll<sup>1</sup>, Lucas BonDurant<sup>1</sup>, Gregory Hinkle<sup>1</sup>, Parsa Akbari<sup>2</sup>, Luca A. Lotta<sup>2</sup>, Regeneron Genetics Center<sup>2\*</sup>, DiscovEHR Collaboration<sup>3</sup>, Aris Baras<sup>2</sup> and Paul Nioi<sup>1</sup>

<sup>1</sup>Alnylam Pharmaceuticals, Cambridge, MA

<sup>2</sup>Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY

<sup>3</sup>Geisinger Health System, Danville, PA

\* For full author and contribution list see Supplementary Information.

## Supplementary Information


### Supplementary Figures

[Supplementary Figure 1: QQ plots for gene-based burden tests.](#)


QQ plots stratified by the number of carriers measured are shown for A) glucose and B) HbA1c. QQ plots stratified by the minimum number of expected case carriers is shown for C) T2D diagnosis. The genomic inflation factor lambda at different thresholds is displayed.

**A**


Glucose: pLOF




Glucose: missense

**B**


HbA1c: pLOF




HbA1c: missense

**C**

T2D: pLOF




T2D: missense




Supplementary Figure 2: Associations with glucose and HbA1c levels from primary care data


Forest plot showing associations with glucose and HbA1c levels as measured in primary care (GP) data. Effect size in standard deviations is shown along with the 95% confidence interval. The threshold for significance is  $p \leq 0.004$  correcting for the number of genes and variant sets tested.





### Supplementary Figure 3: Leave one variant out analysis

Burden tests were run for significant variant sets of interest leaving out one variant at a time. Negative log<sub>10</sub> of the p-value for each test is shown relative to the genomic position of the excluded variant. A) Glucose associations B) HbA1c associations C) T2D associations. pLOF variant sets are labeled as “lof.hc” and damaging missense variant sets as “cadd.25”.






Supplementary Figure 4: Location of variants of interest in *GIGYF1*, *PFAS* and *TNRC6B*  
The locations of individual variants making up the variant sets are plotted with respect to Ensembl  
transcripts. Selected variants are shown as a separate track. A) *GIGYF1* pLOF variants, 7:100687545:CA:C  
shown separately. B) *PFAS* damaging missense variants, 17:8258163:G:A (Glu434Lys) and  
17:8262979:G:A (Ala466Thr) are shown separately. C) *TNRC6B* pLOF variants, 22:40270205:G:T and  
22:40281161:G:T shown separately.


**A****B**

C




### Supplementary Figure 5: Association of drug target genes with HbA1c and T2D

Associations with HbA1c and T2D for variants in 8 genes encoding T2D drug targets (agonist targets: *GLP1R*, *IGF1R*, *PPARG*, *INSR*; antagonist targets: *SLC5A2*, *DPP4*, *KCNJ11*, *ABCC8*). The red line indicates the significance threshold ( $p < 0.003$  correcting for 15 variant sets tested) and the blue line indicates nominal significance of  $p < 0.05$ .



### Supplementary Figure 6: Associations for genes near T2D GWAS loci

All genes in our study are colored grey and the two genes nearest T2D GWAS loci [1] are colored black. Red genes show significant associations with T2D or HbA1c in our study ( $p < 2.41 \times 10^{-5}$ ). Genes shown twice have two variant sets (pLOF and missense) associating with the trait.



## Supplementary Tables

Supplementary Table 1: Numbers of pLOF and damaging missense variants in UKBB

Information for rare variants ( $MAF \leq 1\%$ ) in each subpopulation of UKBB. CADD; combined annotation dependent depletion score.

Population	N pLOF	N pLOF singlets	N genes with pLOF	N missense (CADD $\geq 25$ )	N missense (CADD $\geq 25$ ) singlets	N genes with missense (CADD $\geq 25$ )	N total variant sets (pLOF+missense)
All	726,422	425,081	16,477	2,139,471	1,060,539	17,312	33,789
White	574,950	338,916	16,348	1,691,784	838,024	17,222	33,570
Black	38,888	27,955	8,082	174,550	120,895	14,645	22,727
Asian	47,511	33,045	8,988	212,846	140,152	15,169	24,157
Chinese	9,336	6,841	2,987	53,486	39,008	9,909	12,896

Supplementary Table 2: T2D associations for participants recruited in England

gene	Variant set	title	population	pvalue	OR	95% CI -	95% CI +	n cases	n carrier	n carrier cases	n expected
GCK	missense CADD $\geq 25$	T2D	English recruited	1.38x10 <sup>-8</sup>	3.11	2.1	4.6	22828	177	32	12.59
GCK	pLOF	T2D	English recruited	1.51x10 <sup>-14</sup>	14.63	7.38	29	22828	37	18	2.63
GIGYF1	pLOF	T2D	English recruited	1.24x10 <sup>-10</sup>	4.33	2.77	6.76	22828	111	27	7.89
HNF1A	pLOF	T2D	English recruited	4.05x10 <sup>-10</sup>	5.64	3.28	9.7	22828	67	20	4.77
PAM	missense CADD $\geq 25$	T2D	English recruited	6.34x10 <sup>-13</sup>	1.33	1.23	1.44	22828	8242	751	586.21
TNRC6B	pLOF	T2D	English recruited	6.30x10 <sup>-7</sup>	4.39	2.45	7.85	22828	63	16	4.48

Supplementary Table 3: Conditional analysis for *GIGYF1* and *GCK* variants

gene	variant set	title	adjustment	pvalue	effect (beta/OR)	95% CI -	95% CI +
GIGYF1	pLOF	glucose	GCK pLOF and missense	4.26x10 <sup>-12</sup>	0.62	0.44	0.79
GIGYF1	pLOF	HbA1c	GCK pLOF and missense	1.2x10 <sup>-14</sup>	0.64	0.48	0.80
GIGYF1	pLOF	T2D	GCK pLOF and missense	5.83x10 <sup>-11</sup>	4.16	2.72	6.38

Supplementary Table 4: Glucose, Hba1c and T2D associations for all significant variant sets

For all variant sets significantly associated with at least one diabetes-related trait in our primary analysis, associations with the other traits are shown.

Gene	Variant set	Pvalue glucose	Beta glucose	Pvalue hba1c	Beta hba1c	Pvalue T2D	OR T2D
GCK	pLOF	1.56E-09	0.999	2.64E-17	1.292	2.96E-15	14.16
HNF1A	pLOF	0.01	0.317	2.14E-07	0.592	1.23E-09	5.27
GIGYF1	pLOF	4.42E-12	0.616	1.28E-14	0.639	6.14E-11	4.15
GCK	missense CADD ≥ 25	6.15E-11	0.487	1.86E-17	0.565	1.7E-08	2.96
PAM	missense CADD ≥ 25	0.92	0.001	0.009	0.026	2.26E-12	1.31
IRS2	pLOF	0.07	0.320	1.58E-05	0.687	9.45E-06	5.88
TNRC6B	pLOF	4.01E-05	0.507	2.36E-07	0.582	2E-07	4.44
PDX1	missense CADD ≥ 25	0.02	0.029	2.54E-07	0.060	3.99E-05	1.21
PFAS	missense CADD ≥ 25	0.32	0.009	2.09E-08	-0.048	4.43E-04	0.88
APOB	pLOF	0.36	0.043	6.94E-08	0.232	0.02	1.42
PLD1	pLOF	0.14	0.073	2.99E-07	0.231	0.01	1.50
PTPRH	pLOF	0.69	0.008	4.39E-10	0.109	0.10	1.12
BLVRB	missense CADD ≥ 25	0.49	0.010	2.53E-08	-0.071	0.30	0.95
PLA2G12A	missense CADD ≥ 25	0.39	0.011	5.74E-11	-0.076	0.09	0.92
AMPD3	missense CADD ≥ 25	0.82	0.003	7.28E-34	0.127	0.42	1.04
CARHSP1	missense CADD ≥ 25	0.86	-0.005	6.78E-07	-0.127	0.18	0.86
LCAT	missense CADD ≥ 25	0.81	-0.011	1.29E-11	-0.268	0.31	0.83
RHAG	pLOF	0.10	-0.126	3.31E-34	-0.858	0.21	0.64
ANK1	missense CADD ≥ 25	0.46	-0.012	3.12E-19	-0.129	0.31	0.94
HK1	missense CADD ≥ 25	0.39	0.028	1.08E-07	-0.159	0.14	1.19
AXL	missense CADD ≥ 25	0.93	0.001	4.11E-12	-0.080	0.28	0.95
SLC4A1	missense CADD ≥ 25	0.31	0.032	1.76E-07	-0.154	0.35	1.12
TFR2	missense CADD ≥ 25	0.73	0.009	4.24E-07	-0.124	0.45	0.92
TMC8	missense CADD ≥ 25	0.25	-0.026	3.01E-08	0.114	0.41	0.93
EPB42	pLOF	0.46	-0.050	6.11E-07	-0.307	0.42	1.21
TNFRSF13B	missense CADD ≥ 25	0.98	0.000	4.63E-09	-0.075	0.71	0.98
PFKM	missense CADD ≥ 25	0.52	0.018	2.16E-28	-0.283	0.27	0.88

EPB41	pLOF	0.58	0.038	3.14E-17	-0.529	0.26	1.30
PFKL	missense CADD ≥ 25	0.82	0.003	2.69E-14	0.100	0.86	1.01
APEH	missense CADD ≥ 25	0.30	0.052	1.86E-10	0.290	0.96	1.01
G6PC2	missense CADD ≥ 25	4.62E-83	-0.266	6.71E-45	-0.179	0.97	1.00
PLD1	missense CADD ≥ 25	0.54	0.009	1.51E-10	0.084	0.89	1.01
PIEZ01	missense CADD ≥ 25	0.05	-0.013	9.9E-133	-0.147	0.52	1.02

Supplementary Table 5: OMIM disease associations for genes with a glucose, HbA1c or T2D association

Genes associated with glucose, HbA1c and/or T2D that are implicated in Mendelian disease according to OMIM [2].

gene	Variant set	OMIM ID	OMIM Phenotype
AMPD3	missense CADD ≥ 25	102772	[AMP deaminase deficiency, erythrocytic]
ANK1	missense CADD ≥ 25	612641	Spherocytosis, type 1
APOB	pLOF	107730	Hypobetalipoproteinemia : Hypercholesterolemia, familial, 2
EPB41	pLOF	130500	Elliptocytosis-1
EPB42	pLOF	177070	Spherocytosis, type 5
GCK	pLOF	138079	MODY, type II : Hyperinsulinemic hypoglycemia, familial, 3 : Diabetes mellitus, permanent neonatal : Diabetes mellitus, noninsulin-dependent, late onset
GCK	missense CADD ≥ 25	138079	MODY, type II : Hyperinsulinemic hypoglycemia, familial, 3 : Diabetes mellitus, permanent neonatal : Diabetes mellitus, noninsulin-dependent, late onset
HK1	missense CADD ≥ 25	142600	Hemolytic anemia due to hexokinase deficiency : Retinitis pigmentosa 79 : Neuropathy, hereditary motor and sensory, Russe type
HNF1A	pLOF	142410	Renal cell carcinoma : MODY, type III : Hepatic adenoma, somatic : Diabetes mellitus, insulin-dependent, 20
LCAT	missense CADD ≥ 25	606967	Fish-eye disease : Norum disease
PDX1	missense CADD ≥ 25	600733	Lacticacidemia due to PDX1 deficiency : MODY, type IV : Pancreatic agenesis 1
PFKL	missense CADD ≥ 25	171860	Hemolytic anemia due to phosphofructokinase deficiency
PFKM	missense CADD ≥ 25	610681	Glycogen storage disease VII

PIEZ01	missense CADD ≥ 25	611184	Lymphatic malformation 6 : Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema
PLD1	missense CADD ≥ 25	602382	Cardiac valvular defect, developmental
PLD1	pLOF	602382	Cardiac valvular defect, developmental
RHAG	pLOF	180297	Overhydrated hereditary stomatocytosis : Anemia, hemolytic, Rh-null, regulator type
SLC4A1	missense CADD ≥ 25	109270	Spherocytosis, type 4 : [Blood group, Wright] : Renal tubular acidosis, distal, AR : [Blood group, Waldner] : Renal tubular acidosis, distal, AD : [Blood group, Swann] : Ovalocytosis, SA type : [Blood group, Froese] : Cryohydrocytosis : [Blood group, Diego] : [Malaria, resistance to]
TFR2	missense CADD ≥ 25	604720	Hemochromatosis, type 3
TMC8	missense CADD ≥ 25	605829	Epidermolyticus verruciformis 2
TNFRSF13B	missense CADD ≥ 25	604907	Immunoglobulin A deficiency 2 : Immunodeficiency, common variable, 2

Supplementary Table 6: HbA1c-associated genes and red blood cell traits (supplied as an excel file).

Supplementary Table 7: Glucose and HbA1c associations adjusted for BMI

gene	Variant set	title	adjustment	pvalue	Effect (SD)	95% CI -	95% CI +	N carrier measured
G6PC2	missense CADD ≥ 25	glucose	unadjusted	4.62E-83	-0.27	-0.29	-0.24	5128
G6PC2	missense CADD ≥ 25	glucose	BMI	6.63E-84	-0.26	-0.29	-0.24	5110
GCK	missense CADD ≥ 25	glucose	unadjusted	6.15E-11	0.49	0.34	0.63	173
GCK	missense CADD ≥ 25	glucose	BMI	3.32E-11	0.49	0.34	0.63	173
GCK	pLOF	glucose	unadjusted	1.56E-09	1	0.67	1.32	35
GCK	pLOF	glucose	BMI	3.82E-09	0.96	0.64	1.28	35
GIGYF1	pLOF	glucose	unadjusted	4.42E-12	0.62	0.44	0.79	121
GIGYF1	pLOF	glucose	BMI	1.02E-10	0.57	0.4	0.74	120

G6PC2	missense CADD ≥ 25	HbA1c	unadjusted	6.71E-45	-0.18	-0.2	-0.15	5574
G6PC2	missense CADD ≥ 25	HbA1c	BMI	3.42E-47	-0.18	-0.2	-0.15	5555
GCK	missense CADD ≥ 25	HbA1c	unadjusted	1.86E-17	0.56	0.43	0.69	201
GCK	missense CADD ≥ 25	HbA1c	BMI	9.48E-18	0.55	0.43	0.68	201
GCK	pLOF	HbA1c	unadjusted	2.64E-17	1.29	0.99	1.59	38
GCK	pLOF	HbA1c	BMI	5.94E-17	1.24	0.95	1.53	38
GIGYF1	pLOF	HbA1c	unadjusted	1.28E-14	0.64	0.48	0.8	129
GIGYF1	pLOF	HbA1c	BMI	3.59E-13	0.59	0.43	0.75	128
HNF1A	pLOF	HbA1c	unadjusted	2.14E-07	0.59	0.37	0.82	68
HNF1A	pLOF	HbA1c	BMI	4.60E-08	0.61	0.39	0.82	68
PDX1	missense CADD ≥ 25	HbA1c	unadjusted	2.54E-07	0.06	0.04	0.08	6694
PDX1	missense CADD ≥ 25	HbA1c	BMI	2.88E-08	0.06	0.04	0.08	6673
PFAS	missense CADD ≥ 25	HbA1c	unadjusted	2.09E-08	-0.05	-0.06	-0.03	12621
PFAS	missense CADD ≥ 25	HbA1c	BMI	5.11E-09	-0.05	-0.06	-0.03	12573
TNRC6B	pLOF	HbA1c	unadjusted	2.36E-07	0.58	0.36	0.8	70
TNRC6B	pLOF	HbA1c	BMI	5.16E-07	0.55	0.33	0.76	70

Supplementary Table 8: T2D associations adjusted for BMI

gene	variant set	title	adjustment	pvalue	OR	95% CI -	95% CI +	n cases
GCK	missense CADD ≥ 25	T2D	unadjusted	1.7E-08	2.96	2.03	4.32	24695
GCK	missense CADD ≥ 25	T2D	BMI	2.07E-09	3.34	2.25	4.95	24504
GCK	pLOF	T2D	unadjusted	2.96E-15	14.16	7.33	27.34	24695
GCK	pLOF	T2D	BMI	4.17E-15	16.27	8.11	32.64	24504
GIGYF1	pLOF	T2D	unadjusted	6.14E-11	4.15	2.71	6.37	24695
GIGYF1	pLOF	T2D	BMI	1.38E-09	4.08	2.59	6.43	24504
HNF1A	pLOF	T2D	unadjusted	1.23E-09	5.27	3.08	9	24695
HNF1A	pLOF	T2D	BMI	2.94E-11	6.89	3.9	12.16	24504

PAM	missense CADD ≥ 25	T2D	unadjusted	2.26E-12	1.31	1.21	1.41	24695
PAM	missense CADD ≥ 25	T2D	BMI	4.62E-14	1.35	1.25	1.46	24504
TNRC6B	pLOF	T2D	unadjusted	2.00E-07	4.44	2.53	7.79	24695
TNRC6B	pLOF	T2D	BMI	1.89E-07	4.84	2.67	8.75	24504

Supplementary Table 9: SAIGE-gene results for variant sets of interest

SAIGE-Gene was run in the White population including related individuals. Whether the association is significant at the thresholds used in our primary analysis ( $p \leq 7.82 \times 10^{-7}$  for biomarkers and  $p \leq 1.46 \times 10^{-6}$  for T2D) is indicated.

Gene	Variant set	title	pvalue	significant
G6PC2	missense CADD ≥ 25	glucose	1.30E-99	Y
GCK	missense CADD ≥ 25	glucose	2.01E-11	Y
GCK	pLOF	glucose	6.56E-11	Y
GIGYF1	pLOF	glucose	8.32E-13	Y
G6PC2	missense CADD ≥ 25	HbA1c	1.17E-62	Y
GCK	missense CADD ≥ 25	HbA1c	3.20E-25	Y
GCK	pLOF	HbA1c	1.75E-20	Y
GIGYF1	pLOF	HbA1c	1.92E-22	Y
HNF1A	pLOF	HbA1c	1.52E-08	Y
PDX1	missense CADD ≥ 25	HbA1c	9.05E-12	Y
PFAS	missense CADD ≥ 25	HbA1c	2.00E-10	Y
TNRC6B	pLOF	HbA1c	6.85E-06	N
GCK	missense CADD ≥ 25	T2D	2.33E-09	Y
GCK	pLOF	T2D	3.27E-15	Y
GIGYF1	pLOF	T2D	7.34E-09	Y
HNF1A	pLOF	T2D	3.29E-09	Y
PAM	missense CADD ≥ 25	T2D	5.60E-14	Y
TNRC6B	pLOF	T2D	4.77E-05	N

Supplementary Table 10: Glucose and HbA1c associations excluding diagnosed diabetics

Burden tests for glucose and HbA1c were performed for variants sets of interest excluding individuals diagnosed with any form of diabetes (ICD10 codes E10, E11, E12, E13 and E14).

gene	variant set	title	pvalue	Beta (SD)	95% CI -	95% CI +	n carrier measured
G6PC2	missense	glucose	4.62E-83	-0.27	-0.29	-0.24	5128
G6PC2	missense	glucose non-diabetic	9.03E-97	-0.28	-0.31	-0.25	4758
GCK	missense	glucose	6.15E-11	0.49	0.34	0.63	173
GCK	missense	glucose non-diabetic	2.42E-07	0.40	0.25	0.55	143
GCK	pLOF	glucose	1.56E-09	1.00	0.67	1.32	35
GCK	pLOF	glucose non-diabetic	0.02	0.47	0.07	0.87	20
GIGYF1	pLOF	glucose	4.42E-12	0.62	0.44	0.79	121
GIGYF1	pLOF	glucose non-diabetic	2.95E-08	0.53	0.34	0.72	92

G6PC2	missense	HbA1c	6.71E-45	-0.18	-0.20	-0.15	5574
G6PC2	missense	HbA1c non-diabetic	1.45E-55	-0.19	-0.21	-0.17	5171
GCK	missense	HbA1c	1.86E-17	0.56	0.43	0.69	201
GCK	missense	HbA1c non-diabetic	5.46E-11	0.44	0.31	0.57	166
GCK	pLOF	HbA1c	2.64E-17	1.29	0.99	1.59	38
GCK	pLOF	HbA1c non-diabetic	5.95E-05	0.79	0.41	1.18	19
GIGYF1	pLOF	HbA1c	1.28E-14	0.64	0.48	0.80	129
GIGYF1	pLOF	HbA1c non-diabetic	8.29E-07	0.43	0.26	0.60	99
HNF1A	pLOF	HbA1c	2.14E-07	0.59	0.37	0.82	68
HNF1A	pLOF	HbA1c non-diabetic	0.013	0.30	0.06	0.54	50
PDX1	missense	HbA1c	2.54E-07	0.06	0.04	0.08	6694
PDX1	missense	HbA1c non-diabetic	4.54E-04	0.04	0.02	0.06	6132
PFAS	missense	HbA1c	2.09E-08	-0.05	-0.06	-0.03	12621
PFAS	missense	HbA1c non-diabetic	1.9E-07	-0.04	-0.06	-0.03	11790
TNRC6B	pLOF	HbA1c	2.36E-07	0.58	0.36	0.80	70
TNRC6B	pLOF	HbA1c non-diabetic	0.009	0.31	0.08	0.55	52

Supplementary Table 11: Glucose and HbA1c associations from primary care data

Associations with glucose and HbA1c measurements obtained from primary care (GP) data. Whether the association is significant adjusting for the number of variant sets and traits tested ( $p \leq 0.004$ ) is indicated.

gene	Variant set	title	pvalue	beta	95% CI -	95% CI +	N carrier measured	significant
GIGYF1	pLOF	Glucose GP	2.1E-06	0.65	0.38	0.92	50	Y
GCK	pLOF	Glucose GP	1.41E-08	1.29	0.85	1.74	18	Y
GCK	missense	Glucose GP	0.00253	0.36	0.13	0.59	67	Y
G6PC2	missense	Glucose GP	1.6E-20	-0.19	-0.23	-0.15	2192	Y
G6PC2	missense	HbA1c GP	4.14E-06	-0.13	-0.19	-0.08	1169	Y
GCK	pLOF	HbA1c GP	3.9E-06	1.12	0.65	1.60	16	Y
GCK	missense	HbA1c GP	0.0625	0.26	-0.01	0.53	50	N
GIGYF1	pLOF	HbA1c GP	1.19E-05	0.74	0.41	1.07	33	Y
HNF1A	pLOF	HbA1c GP	5.68E-04	0.65	0.28	1.01	27	Y
PDX1	missense	HbA1c GP	0.003	0.08	0.03	0.13	1385	Y
PFAS	missense	HbA1c GP	0.001	-0.06	-0.10	-0.02	2679	Y
TNRC6B	pLOF	HbA1c GP	0.01	0.58	0.13	1.03	18	N

Supplementary Table 12: T2D associations for novel genes in Geisinger Health System

For novel genes associated with diabetes traits in our primary analysis we tested relevant variant sets for association with T2D diagnosis in Geisinger Health System (GHS). Variant set definitions and analysis methods varied somewhat from our primary analysis (see Methods).

Phenotype	Gene	Variant set	pvalue	OR (95% CI)	MAF (%)	Genotype counts cases, RR RA AA genotypes	Genotype counts controls, RR RA AA genotypes
T2D	GIGYF1	pLOF; MAF < 1%	0.01	1.8 (1.1, 2.8)	0.05%	25,808 38 0	63,697 52 0
T2D	TNRC6B	pLOF; MAF < 1%	0.66	1.1 (0.8, 1.4)	0.16%	25,775 71 0	63,531 218 0
T2D	PFAS	pLOF plus deleterious missense; MAF < 1%	0.29	1 (0.96, 1.1)	1.78%	24,898 946 2	61,512 2,233 4

Supplementary Table 13: Association results when singletons are excluded

gene	Variant set	Included variants	phenotype	pvalue	effect (beta/OR)	n carrier	significant
GCK	missense CADD ≥ 25	All	T2D	1.70E-08	2.96	202	Y
GCK	missense CADD ≥ 25	No singletons	T2D	3.04E-04	2.29	166	N
GCK	pLOF	All	T2D	2.96E-15	14.16	40	Y
GCK	pLOF	No singletons	T2D	2.57E-07	10.88	21	Y
GIGYF1	pLOF	All	T2D	6.14E-11	4.15	131	Y
GIGYF1	pLOF	No singletons	T2D	2.91E-05	3.64	72	N
HNF1A	pLOF	All	T2D	1.23E-09	5.27	73	Y
HNF1A	pLOF	No singletons	T2D	2.34E-08	5.21	63	Y
PAM	missense CADD ≥ 25	All	T2D	2.26E-12	1.31	9357	Y
PAM	missense CADD ≥ 25	No singletons	T2D	4.1E-12	1.30	9257	Y
TNRC6B	pLOF	All	T2D	2E-07	4.44	71	Y
TNRC6B	pLOF	No singletons	T2D	0.69	1.36	23	N
G6PC2	missense CADD ≥ 25	All	glucose	4.62E-83	-0.27	5128	Y
G6PC2	missense CADD ≥ 25	No singletons	glucose	1.12E-82	-0.27	5103	Y
GCK	missense CADD ≥ 25	All	glucose	6.15E-11	0.49	173	Y
GCK	missense CADD ≥ 25	No singletons	glucose	6.98E-05	0.33	142	N
GCK	pLOF	All	glucose	1.56E-09	1.00	35	Y
GCK	pLOF	No singletons	glucose	0.0015	0.69	20	N
GIGYF1	pLOF	All	glucose	4.42E-12	0.62	121	Y
GIGYF1	pLOF	No singletons	glucose	1.54E-05	0.52	66	N
G6PC2	missense CADD ≥ 25	All	HbA1c	6.71E-45	-0.18	5574	Y
G6PC2	missense CADD ≥ 25	No singletons	HbA1c	9.98E-45	-0.18	5548	Y
GCK	missense CADD ≥ 25	All	HbA1c	1.86E-17	0.56	201	Y
GCK	missense CADD ≥ 25	No singletons	HbA1c	6.13E-09	0.43	165	Y
GCK	pLOF	All	HbA1c	2.64E-17	1.29	38	Y
GCK	pLOF	No singletons	HbA1c	1.16E-05	0.90	21	N
GIGYF1	pLOF	All	HbA1c	1.28E-14	0.64	129	Y

GIGYF1	pLOF	No singletons	HbA1c	5.47E-09	0.65	72	Y
HNF1A	pLOF	All	HbA1c	2.14E-07	0.59	68	Y
HNF1A	pLOF	No singletons	HbA1c	4.75E-06	0.56	59	N
PDX1	missense CADD ≥ 25	All	HbA1c	2.54E-07	0.06	6694	Y
PDX1	missense CADD ≥ 25	No singletons	HbA1c	4.75E-07	0.06	6662	Y
PFAS	missense CADD ≥ 25	All	HbA1c	2.09E-08	-0.05	12621	Y
PFAS	missense CADD ≥ 25	No singletons	HbA1c	7.07E-08	-0.05	12493	Y
TNRC6B	pLOF	All	HbA1c	2.36E-07	0.58	70	Y
TNRC6B	pLOF	No singletons	HbA1c	0.09	0.34	23	N

Supplementary Table 14: Associations for variants in *SLC30A8* and *MC4R*

We examined glucose, HbA1c and T2D associations for *SLC30A8* and *MC4R*, genes reported to associate with T2D by Flannick and colleagues [3].

variant set	title	pvalue	effect (SD/OR)	95% CI -	95% CI +	n carrier measured	n carrier cases	n expected
SLC30A8 pLOF	HbA1c	1.44E-05	-0.28	-0.41	-0.15	213		
SLC30A8 pLOF	glucose	0.003	-0.20	-0.33	-0.07	209		
SLC30A8 pLOF	T2D	0.03	0.42	0.20	0.91		7	15.81
SLC30A8 missense	HbA1c	6.16E-06	-0.18	-0.26	-0.10	554		
SLC30A8 missense	glucose	2.51E-04	-0.16	-0.25	-0.08	493		
SLC30A8 missense	T2D	0.06	0.69	0.47	1.01	577	28	39.15
SLC30A8 pLOF+missense	HbA1c	8.64E-10	-0.21	-0.28	-0.14	767		
SLC30A8 pLOF+missense	glucose	2.71E-06	-0.17	-0.25	-0.10	702		
SLC30A8 pLOF+missense	T2D	0.005	0.61	0.44	0.86		35	54.96
MC4R missense	HbA1c	0.19	0.04	-0.02	0.10	872		
MC4R missense	glucose	0.78	0.01	-0.06	0.08	787		
MC4R missense	T2D	0.27	1.15	0.90	1.46		73	62.56

Supplementary Table 15: Drug target gene associations with HbA1c and T2D

HbA1c and T2D associations for pLOF and damaging missense variants in the genes encoding T2D drug targets.

\*\*p < 0.003 (significance correcting for 15 variant sets tested)

\*p<0.05 (nominal significance)

Variant set	title	pvalue	Effect (beta/OR)	95% CI -	95% CI +	N carrier measured or N carrier cases/N expected	Significance

DPP4 pLOF	HbA1c	1.4E-05	-0.20	-0.29	-0.11	424	**
GLP1R missense	HbA1c	0.002	0.10	0.04	0.16	869	**
IGF1R pLOF	HbA1c	0.01	0.25	0.06	0.44	91	*
IGF1R missense	HbA1c	0.02	0.05	0.01	0.09	2145	*
DPP4 missense	HbA1c	0.09	-0.04	-0.08	0.01	2085	
ABCC8 pLOF	HbA1c	0.14	0.08	-0.03	0.20	274	
KCNJ11 missense	HbA1c	0.47	0.03	-0.05	0.10	584	
SLC5A2 pLOF	HbA1c	0.57	-0.03	-0.14	0.08	306	
INSR missense	HbA1c	0.60	0.01	-0.04	0.07	1253	
ABCC8 missense	HbA1c	0.60	0.01	-0.03	0.06	1718	
INSR pLOF	HbA1c	0.64	0.04	-0.12	0.20	133	
SLC5A2 missense	HbA1c	0.73	-0.01	-0.06	0.04	1485	
PPARG pLOF	HbA1c	0.80	-0.06	-0.52	0.40	16	
GLP1R pLOF	HbA1c	0.83	-0.02	-0.22	0.18	86	
PPARG missense	HbA1c	0.90	0.01	-0.16	0.18	119	
KCNJ11 missense	T2D	2.19E-04	1.65	1.26	2.15	63/42.27	**
PPARG pLOF	T2D	0.007	5.08	1.56	16.54	4/1.09	*
IGF1R missense	T2D	0.01	1.22	1.05	1.43	181/152.18	*
GLP1R missense	T2D	0.02	1.32	1.04	1.67	78/61.94	*
INSR pLOF	T2D	0.03	1.80	1.06	3.06	16/9.16	*
ABCC8 missense	T2D	0.04	1.20	1.01	1.43	143/121.92	*
PPARG missense	T2D	0.06	1.77	0.98	3.17	13/8.41	
INSR missense	T2D	0.16	0.84	0.67	1.07	77/89.08	
DPP4 missense	T2D	0.36	1.08	0.92	1.27	159/148.32	
SLC5A2 pLOF	T2D	0.39	0.81	0.50	1.31	18/21.98	
GLP1R pLOF	T2D	0.58	1.24	0.57	2.72	7/5.97	
IGF1R pLOF	T2D	0.68	1.17	0.56	2.42	8/6.65	
DPP4 pLOF	T2D	0.74	0.94	0.65	1.37	30/30.53	
ABCC8 pLOF	T2D	0.78	0.94	0.58	1.50	19/19.54	
SLC5A2 missense	T2D	0.97	1.00	0.82	1.23	104/105.37	

Supplementary Table 16: *GIGYF1* pLOF associations with cholesterol levels

The association of *GIGYF1* pLOF with total and LDL cholesterol was tested 1) adjusting for use of cholesterol-lowering medication and 2) excluding those on cholesterol-lowering medication from the analysis.

gene	variant set	title	adjustment/subset	pvalue	beta	95% CI -	95% CI +	n carrier measured
GIGYF1	pLOF	total cholesterol	unadjusted	2.44E-12	-0.61	-0.78	-0.44	128
GIGYF1	pLOF	LDL cholesterol	unadjusted	2.40E-10	-0.56	-0.73	-0.38	128
GIGYF1	pLOF	total cholesterol	adjusted cholesterol medication	4.14E-11	-0.52	-0.67	-0.36	128

GIGYF1	pLOF	LDL cholesterol	adjusted cholesterol medication	4.68E-09	-0.46	-0.62	-0.31	128
GIGYF1	pLOF	total cholesterol	exclude cholesterol medication	3.70E-07	-0.46	-0.63	-0.28	96
GIGYF1	pLOF	LDL cholesterol	exclude cholesterol medication	1.54E-05	-0.39	-0.57	-0.21	96

Supplementary Table 17: rs221783 is an eQTL for *GIGYF1*

GTEX eQTL data for rs221783 in selected tissues. The nominal p-value is shown along with the slope from the linear regression (giving direction of effect) and standard error (SE) for the T allele. In all cases, rs221783 is highly or completely correlated with the best eQTL for *GIGYF1* as shown in the “R<sup>2</sup> with best” column.

Tissue	rsid	GTEx variant id	gene name	pvalue	Slope (T allele)	Slope SE	rsid for best eQTL	R <sup>2</sup> with best
Adipose - subcutaneous	rs221783	chr7_100695291_T_C_b38	<i>GIGYF1</i>	1.57x10 <sup>-30</sup>	0.35	0.03	rs221781	1.00
Lung	rs221783	chr7_100695291_T_C_b38	<i>GIGYF1</i>	1.00x10 <sup>-17</sup>	0.32	0.04	rs221774	1.00
Pancreas	rs221783	chr7_100695291_T_C_b38	<i>GIGYF1</i>	6.40x10 <sup>-10</sup>	0.38	0.06	rs221786	0.96
Thyroid	rs221783	chr7_100695291_T_C_b38	<i>GIGYF1</i>	1.14x10 <sup>-26</sup>	0.37	0.03	rs221798	1.00

Supplementary Table 18: Conditional analysis of common variant and *GIGYF1* pLOF

Conditional analysis was performed in individuals from the White subset with array genotypes, exome sequencing data and biomarker measurements available.

phenotype	Variants(s)	adjustment	pvalue	Beta (SD)
glucose	<i>GIGYF1</i> pLOF	adj rs221783	5.29E-12	0.71
glucose	<i>GIGYF1</i> pLOF	unadjusted	5.66E-12	0.71
HbA1c	<i>GIGYF1</i> pLOF	adj rs221783	6.38E-12	0.65
HbA1c	<i>GIGYF1</i> pLOF	unadjusted	6.83E-12	0.65
glucose	rs221783	adj pLOF	1.41E-10	-0.03
glucose	rs221783	unadjusted	1.51E-10	-0.03
HbA1c	rs221783	adj pLOF	9.26E-07	-0.02
HbA1c	rs221783	unadjusted	9.91E-07	-0.02

Supplementary Table 19: Replication of rs221783 associations and meta-analysis

dataset	phenotype	chr	pos (hg19/hg38)	Ref (effect allele)	Alt	rsid	MAF	pvalue	effect in SD or OR (95% CI)
UKBB	Glucose	7	100292914/100695291	T	C	rs221783	11.0%	1.82x10 <sup>-11</sup>	-0.03 (-0.03, -0.02)
Biobank Japan	Glucose (blood sugar)	7	100292914/100695291	T	C	rs221783	3.5%	1.71x10 <sup>-4</sup>	-0.05 (-0.07, -0.02)

UKBB+Japan	Glucose	7	100292914/ 100695291	T	C	rs221783	-	$4.43 \times 10^{-14}$	-0.03 (-0.04, -0.02)
UKBB	T2D (ICD10 E11)	7	100292914/ 100695291	T	C	rs221783	11.0%	0.005	0.96 (0.93, 0.99)
FinnGen R3	T2D (E4 DM2)	7	100292914/ 100695291	T	C	rs221783	15.4%	0.02	0.96 (0.93, 0.99)
UKBB+FinnGen	T2D	7	100292914/ 100695291	T	C	rs221783	-	$2.98 \times 10^{-4}$	0.99 (0.94, 0.98)

### Supplementary Table 20: Identification of causal genes at T2D GWAS loci

T2D and HbA1c associations for pLOF and missense variants in the two genes closest to T2D GWAS hits [1] were examined. Significant results are shown ( $p \leq 2.41 \times 10^{-5}$  adjusting for 2071 variant sets tested).

Variant set	title	pvalue	effect (beta/OR)	95% CI -	95% CI +
ANK1 missense	HbA1c	3.12E-19	-0.13	-0.16	-0.10
GCK missense	HbA1c	1.86E-17	0.56	0.43	0.69
GCK pLOF	HbA1c	2.64E-17	1.29	0.99	1.59
HNF1A pLOF	HbA1c	2.14E-07	0.59	0.37	0.82
TNRC6B pLOF	HbA1c	2.36E-07	0.58	0.36	0.80
CFTR pLOF	HbA1c	1.4E-06	-0.10	-0.15	-0.06
SLC30A8 missense	HbA1c	6.16E-06	-0.18	-0.26	-0.10
NF1 pLOF	HbA1c	1.27E-05	-0.25	-0.37	-0.14
SLC30A8 pLOF	HbA1c	1.44E-05	-0.28	-0.41	-0.15
IRS2 pLOF	HbA1c	1.58E-05	0.69	0.38	1.00
GCK pLOF	T2D	2.96E-15	14.16	7.33	27.34
HNF1A pLOF	T2D	1.23E-09	5.27	3.08	9.00
GCK missense	T2D	1.7E-08	2.96	2.03	4.32
TNRC6B pLOF	T2D	2.00E-07	4.44	2.53	7.79
IRS2 pLOF	T2D	9.45E-06	5.88	2.69	12.89
HNF4A missense	T2D	1.01E-05	1.52	1.26	1.84

### Supplementary Note

We examined the quality and location of individual variants in the following sets; *GIGYF1* pLOF, *TNRC6B* pLOF and *PFAS* damaging missense variants.

For *GIGYF1*, all pLOF variants overlapped both *GIGYF1* protein-coding transcripts. The most common *GIGYF1* pLOF variant in our data (rs770150936, hg38 7:100687545:CA:C, MAF = 0.0054%), carried by 39 people, is predicted to result in a frameshift and premature termination of translation at position 234 (ENSP00000275732.4:p.Leu111ArgfsTer234). We examined quality metrics for this variant and found that it was sequenced to a mean depth of 33x and had an allele quality score of 1142 (in 70th percentile for quality). The 7:100687545:CA:C variant is present in gnomAD v2.1.1 and v3 and has a frequency in the non-Finnish European population of 0.0048% and 0.0031% respectively.

For *PFAS*, the missense variants contributing most to the association with HbA1c are hg38 17:8258163:G:A (rs141777945, MAF = 0.2%) resulting in a glutamate to lysine substitution at position 434 (ENSP00000313490.6:p.Glu434Lys) and hg38 17:8262979:G:A (rs34939404, MAF = 0.7%) resulting in an alanine to threonine substitution at position 466 (ENSP00000313490.6:p.Ala466Thr). These variants were sequenced to a mean depth of 31x and 24x respectively and both had quality scores in the 75<sup>th</sup> percentile. Both are present at similar frequencies in gnomAD. These missense variants affect the longest protein-coding *PFAS* transcript ENST00000314666 (canonical and MANE select transcript).

Individual *TNRC6B* pLOF variants tended to be rare with the most common variants carried by just 9 (hg38 22:40270205:G:T; NP\_001020014.1:p.Glu217Ter) and 7 (hg38 22:40281161:G:T NP\_001155973.1:p.Glu1152Ter) individuals in White population respectively. This is consistent with the fact that the gene is constrained (pLI=1 and LOEUF=0.17). Both variants were sequenced to a mean depth of at least 42x and had high quality scores. Only 22:40281161:G:T is present in gnomAD and is flagged by the LOFTEE algorithm as potentially occurring in a misannotated exon (PHYLOCSF\_UNLIKELY\_ORF). Strikingly, 48 out of 71 carriers tested carried singleton variants. The large number of singletons together with the fact that *TNRC6B* is constrained suggest that some of these pLOF variants may not result in true loss of function or be due to sequencing errors.

## Regeneron Genetics Center Banner Author List and Contribution Statements

All authors/contributors are listed in alphabetical order.

### **RGC Management and Leadership Team**

Goncalo Abecasis, Aris Baras, Michael Cantor, Giovanni Coppola, Aris Economides, Luca A. Lotta, John D. Overton, Jeffrey G. Reid, Alan Shuldiner, Katia Karalis and Katherine Siminovitch, .

Contribution: All authors contributed to securing funding, study design and oversight. All authors reviewed the final version of the manuscript.

### **Sequencing and Lab Operations**

Christina Beechert, Caitlin Forsythe, M.S., Erin D. Fuller, Zhenhua Gu, M.S., Michael Lattari, Alexander Lopez, M.S., John D. Overton, Thomas D. Schleicher, M.S., Maria Sotiropoulos Padilla, M.S., Louis Widom, Sarah E. Wolf, M.S., Manasi Pradhan, M.S., Kia Manoochehri, Ricardo H. Ulloa.

Contribution: C.B., C.F., A.L., and J.D.O. performed and are responsible for sample genotyping. C.B., C.F., E.D.F., M.L., M.S.P., L.W., S.E.W., A.L., and J.D.O. performed and are responsible for exome sequencing. T.D.S., Z.G., A.L., and J.D.O. conceived and are responsible for laboratory automation. M.S.P., K.M., R.U., and J.D.O are responsible for sample tracking and the library information management system.

### **Genome Informatics**

Xiaodong Bai, Suganthi Balasubramanian, Andrew Blumenfeld, Boris Boutkov, Gisu Eom, Lukas Habegger, Alicia Hawes, B.S., Shareef Khalid, Olga Krasheninina, M.S., Rouel Lanche, Adam J. Mansfield,

B.A., Evan K. Maxwell, Mrunali Nafde, Sean O'Keeffe, M.S., Max Orelus, Razvan Panea, Tommy Polanco, B.A., Ayesha Rasool, M.S., Jeffrey G. Reid, William Salerno, Jeffrey C. Staples,

Contribution: X.B., A.H., O.K., A.M., S.O., R.P., T.P., A.R., W.S. and J.G.R. performed and are responsible for the compute logistics, analysis and infrastructure needed to produce exome and genotype data. G.E., M.O., M.N. and J.G.R. provided compute infrastructure development and operational support. S.B., S.K., and J.G.R. provide variant and gene annotations and their functional interpretation of variants. E.M., J.S., R.L., B.B., A.B., L.H., J.G.R. conceived and are responsible for creating, developing, and deploying analysis platforms and computational methods for analyzing genomic data.

### **Clinical Informatics**

Michael Cantor and Dadong Li

Contribution: All authors contributed to developing the phenotype definitions.

### **Translational Genetics:**

Adam Locke, Niek Verweij, Jonas Nielsen, Jonas Bovijn, Tانيا De, Mary Haas, Parsa Akbari and Olukayode Sosina

Contribution: All authors contributed to the analytical analysis of the project.

### **Research Program Management**

Marcus B. Jones, Jason Mighty, Michelle G. LeBlanc, and Lyndon J. Mitnaul,

Contribution: All authors contributed to the management and coordination of all research activities, planning and execution. All authors contributed to the review process for the final version of the manuscript.

## **References**

1. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet*. 2020;52(7):680-91. Epub 2020/06/17. doi: 10.1038/s41588-020-0637-y. PubMed PMID: 32541925; PubMed Central PMCID: PMCPMC7343592.
2. McKusick-Nathans Institute of Genetic Medicine JHUB, MD). Online Mendelian Inheritance in Man, OMIM. <https://omim.org/>.
3. Flannick J, Mercader JM, Fuchsberger C, Udler MS, Mahajan A, Wessel J, et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. *Nature*. 2019;570(7759):71-6. Epub 2019/05/24. doi: 10.1038/s41586-019-1231-2. PubMed PMID: 31118516; PubMed Central PMCID: PMCPMC6699738.